In a first, AstraZeneca gains rights to an antisense KRAS drug in $165M Ionis deal
AstraZeneca is handing over $28 million to Ionis in exchange for rights to develop one of its early-stage cancer drugs. The pharma giant has also committed up to $137 million in development and regulatory milestones for ONIS-KRAS-2.5Rx, or AZD4785, after wrapping up IND-supporting studies.
The drug targets KRAS, which spawns genetic mutations that figure prominently in cancer cases, giving AstraZeneca boasting rights to the first antisense drug with KRAS as a target that will enter clinical development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.